Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Artigo em Coreano | WPRIM | ID: wpr-738953

RESUMO

BACKGROUND/AIMS: A previous study showed that dietary intervention with Artemisia and green tea extracts, i.e., SD1003F, relieved Helicobacter pylori-associated chronic atrophic gastritis in a mouse model. We continue the research through the current randomized double-blind clinical trial to evaluate the efficacy and safety of the intervention for H. pylori-associated gastric discomfort. MATERIALS AND METHODS: Forty-nine volunteers who tested positive for H. pylori infection received either placebo or SD1003F for 10 weeks and their functional dyspepsia-related quality of life (QOL) was evaluated. H. pylori infection using a urea breath test (UBT), measurement of pepsinogen level using GastroPanel. Adverse effects with biochemical changes were also evaluated. RESULTS: SD1003F administration significantly improved health related-QOL, including dietary intake, emotional stability, life pattern, and social factors relevant to gastric discomfort, in comparison to the control (P < 0.05). The mean UBT measurement significantly decreased in the SD1003F group (P < 0.05). In 2 of the 24 volunteers, SD1003F alone eradicated H. pylori infection, with significant improvements in endoscopic findings. GastroPanel analysis revealed significant improvements that reflect rejuvenation of gastric atrophy in the SD1003F group. No significant side effect was observed in any participant. CONCLUSIONS: SD1003F (Artemisia and green tea extract), is a potential phytochemical to improve H. pylori-associated gastric discomfort.


Assuntos
Animais , Camundongos , Artemisia , Atrofia , Testes Respiratórios , Gastrite Atrófica , Helicobacter pylori , Helicobacter , Pepsinogênio A , Qualidade de Vida , Rejuvenescimento , Chá , Ureia , Voluntários
2.
Artigo em Coreano | WPRIM | ID: wpr-177309

RESUMO

PURPOSE: We compare the effectiveness and safety of transurethral resection of the prostate(TURP) with those of open prostatectomy for large benign prostatic hyperplasia(BPH), that was over 70cc of prostate volume. MATERIALS AND METHODS: Seventy-one patients with a prostate volume of more than 70cc and who received TURP were classified to group A, while 41 patients who received open prostatectomy were classified to group B. The International Prostate Symptom Score(IPSS), maximal flow rate(Qmax) and post-voiding residual urine(PVR) volume were evaluated preoperatively and at 1, 3, 5 and over 5 years postoperatively. RESULTS: The postoperative IPSS, Qmax and PVR were significantly improved after 1 year(p0.05). The PVR was significantly lower in group B at 1 year post-operation(p0.05). There were 7 cases(9.8%) of re-operation and 3 cases(4.2%) of re-medication after 5 years of operation. There were no major complications for each group. CONCLUSIONS: On comparison between TURP and open prostatectomy for the patients with large BPH, there were no significant difference in effectiveness and safety for 5 years. Even for the patients with BPH that showed a high volume, TURP is an effective operation that can replace open prostatectomy.


Assuntos
Humanos , Próstata , Prostatectomia , Hiperplasia Prostática , Ressecção Transuretral da Próstata
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA